- Home
- NMFC vs ANAB Comparison
NMFC vs ANAB Comparison
Compare NMFC & ANAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NMFC
- ANAB
- Stock Information
- Founded
- NMFC 2010
- ANAB 2005
- Country
- NMFC United States
- ANAB United States
- Employees
- NMFC N/A
- ANAB N/A
- Industry
- NMFC Finance/Investors Services
- ANAB Biotechnology: Pharmaceutical Preparations
- Sector
- NMFC Finance
- ANAB Health Care
- Exchange
- NMFC Nasdaq
- ANAB Nasdaq
- Market Cap
- NMFC 972.8M
- ANAB 1.0B
- IPO Year
- NMFC 2011
- ANAB 2017
- Fundamental
- Price
- NMFC $9.56
- ANAB $40.91
- Analyst Decision
- NMFC Hold
- ANAB Buy
- Analyst Count
- NMFC 4
- ANAB 12
- Target Price
- NMFC $10.00
- ANAB $63.80
- AVG Volume (30 Days)
- NMFC 607.2K
- ANAB 734.2K
- Earning Date
- NMFC 11-03-2025
- ANAB 11-04-2025
- Dividend Yield
- NMFC 13.52%
- ANAB N/A
- EPS Growth
- NMFC N/A
- ANAB N/A
- EPS
- NMFC 0.66
- ANAB N/A
- Revenue
- NMFC $340,877,000.00
- ANAB $169,467,000.00
- Revenue This Year
- NMFC N/A
- ANAB $37.52
- Revenue Next Year
- NMFC N/A
- ANAB N/A
- P/E Ratio
- NMFC $14.42
- ANAB N/A
- Revenue Growth
- NMFC N/A
- ANAB 196.42
- 52 Week Low
- NMFC $8.84
- ANAB $12.21
- 52 Week High
- NMFC $12.05
- ANAB $43.31
- Technical
- Relative Strength Index (RSI)
- NMFC 54.33
- ANAB 69.33
- Support Level
- NMFC $8.98
- ANAB $33.10
- Resistance Level
- NMFC $9.24
- ANAB $43.31
- Average True Range (ATR)
- NMFC 0.19
- ANAB 3.12
- MACD
- NMFC 0.00
- ANAB 0.43
- Stochastic Oscillator
- NMFC 71.34
- ANAB 85.09
About NMFC New Mountain Finance Corporation
New Mountain Finance Corp is a closed-end, non-diversified management investment company. It invests in equity interests such as preferred stock, common stock, warrants, or options received in connection with debt investments or may include direct investment in the equity of private companies. The company's investment objective is to generate current income and capital appreciation through sourcing and origination of debt securities at all levels of the capital structure, including first and second-lien debt, notes, bonds and mezzanine securities.
About ANAB AnaptysBio Inc.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).